|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ezetimibe]] |
| {{Ezetimibe}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Use In Specific Populations==
| |
| ===Pregnancy===
| |
| | |
| '''Pregnancy Category C'''
| |
| | |
| There are no adequate and well-controlled studies of ezetimibe in pregnant women. Ezetimibe should be used during pregnancy only if the potential benefit justifies the risk to the fetus.
| |
| | |
| In oral (gavage) embryo-fetal development studies of ezetimibe conducted in rats and rabbits during organogenesis, there was no evidence of embryolethal effects at the doses tested (250, 500, 1000 mg/kg/day). In rats, increased incidences of common fetal skeletal findings (extra pair of thoracic ribs, unossified cervical vertebral centra, shortened ribs) were observed at 1000 mg/kg/day (~10 × the human exposure at 10 mg daily based on AUC0–24hr for total ezetimibe). In rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 × the human exposure at 10 mg daily based on AUC0–24hr for total ezetimibe). Ezetimibe crossed the placenta when pregnant rats and rabbits were given multiple oral doses.
| |
| | |
| Multiple-dose studies of ezetimibe given in combination with [[statins]] in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. Reproductive findings occur at lower doses in combination therapy compared to monotherapy.
| |
| | |
| All [[statins]] are contraindicated in pregnant and nursing women. When ZETIA is administered with a statin in a woman of childbearing potential, refer to the pregnancy category and product labeling for the statin. [See Contraindications (4).]
| |
| | |
| ===Nursing Mothers===
| |
| | |
| It is not known whether ezetimibe is excreted into human breast milk. In rat studies, exposure to total ezetimibe in nursing pups was up to half of that observed in maternal plasma. Because many drugs are excreted in human milk, caution should be exercised when ZETIA is administered to a nursing woman. ZETIA should not be used in nursing mothers unless the potential benefit justifies the potential risk to the infant.
| |
| | |
| ===Pediatric Use===
| |
| | |
| The effects of ZETIA coadministered with [[simvastatin]] (n=126) compared to [[simvastatin]] monotherapy (n=122) have been evaluated in adolescent boys and girls with [[heterozygous familial hypercholesterolemia]] (HeFH). In a multicenter, double-blind, controlled study followed by an open-label phase, 142 boys and 106 postmenarchal girls, 10 to 17 years of age (mean age 14.2 years, 43% females, 82% Caucasians, 4% Asian, 2% Blacks, 13% multi-racial) with HeFH were randomized to receive either ZETIA coadministered with [[simvastatin]] or [[simvastatin]] monotherapy. Inclusion in the study required 1) a baseline LDL-C level between 160 and 400 mg/dL and 2) a medical history and clinical presentation consistent with HeFH. The mean baseline LDL-C value was 225 mg/dL (range: 161–351 mg/dL) in the ZETIA coadministered with [[simvastatin]] group compared to 219 mg/dL (range: 149–336 mg/dL) in the [[simvastatin]] monotherapy group. The patients received coadministered ZETIA and [[simvastatin]] (10 mg, 20 mg, or 40 mg) or [[simvastatin]] monotherapy (10 mg, 20 mg, or 40 mg) for 6 weeks, coadministered ZETIA and 40-mg [[simvastatin]] or 40-mg [[simvastatin]] monotherapy for the next 27 weeks, and open-label coadministered ZETIA and [[simvastatin]] (10 mg, 20 mg, or 40 mg) for 20 weeks thereafter.
| |
| | |
| The results of the study at Week 6 are summarized in Table 3. Results at Week 33 were consistent with those at Week 6.
| |
| {|
| |
| |[[File:zetia03.jpg|thumb|800px]]
| |
| |}
| |
| From the start of the trial to the end of Week 33, discontinuations due to an adverse reaction occurred in 7 (6%) patients in the ZETIA coadministered with simvastatin
| |
| | |
| group and in 2 (2%) patients in the [[simvastatin]] monotherapy group.
| |
| | |
| During the trial, hepatic transaminase elevations (two consecutive measurements for ALT and/or AST ≥3 × ULN) occurred in four (3%) individuals in the ZETIA coadministered with [[simvastatin]] group and in two (2%) individuals in the [[simvastatin]] monotherapy group. Elevations of CPK (≥10 × ULN) occurred in two (2%) individuals in the ZETIA coadministered with [[simvastatin]] group and in zero individuals in the [[simvastatin]] monotherapy group.
| |
| | |
| In this limited controlled study, there was no significant effect on growth or sexual maturation in the adolescent boys or girls, or on menstrual cycle length in girls.
| |
| | |
| Coadministration of ZETIA with [[simvastatin]] at doses greater than 40 mg/day has not been studied in adolescents. Also, ZETIA has not been studied in patients younger than 10 years of age or in pre-menarchal girls.
| |
| | |
| Based on total ezetimibe (ezetimibe + ezetimibe-glucuronide), there are no pharmacokinetic differences between adolescents and adults. Pharmacokinetic data in the pediatric population <10 years of age are not available.
| |
| | |
| ===Geriatric Use===
| |
| | |
| ====Monotherapy Studies====
| |
| | |
| Of the 2396 patients who received ZETIA in clinical studies, 669 (28%) were 65 and older, and 111 (5%) were 75 and older.
| |
| | |
| ====Statin Coadministration Studies====
| |
| | |
| Of the 11,308 patients who received ZETIA + [[statin]] in clinical studies, 3587 (32%) were 65 and older, and 924 (8%) were 75 and older.
| |
| | |
| No overall differences in safety and effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3)].
| |
| | |
| ===Renal Impairment===
| |
| | |
| When used as monotherapy, no dosage adjustment of ZETIA is necessary.
| |
| | |
| In the Study of Heart and Renal Protection (SHARP) trial of 9270 patients with moderate to severe renal impairment (6247 non-dialysis patients with median serum creatinine 2.5 mg/dL and median estimated glomerular filtration rate 25.6 mL/min/1.73 m2, and 3023 dialysis patients), the incidence of serious adverse events, adverse events leading to discontinuation of study treatment, or adverse events of special interest (musculoskeletal adverse events, liver enzyme abnormalities, incident cancer) was similar between patients ever assigned to ezetimibe 10 mg plus [[simvastatin]] 20 mg (n=4650) or placebo (n=4620) during a median follow-up of 4.9 years. However, because renal impairment is a risk factor for statin-associated myopathy, doses of [[simvastatin]] exceeding 20 mg should be used with caution and close monitoring when administered concomitantly with ZETIA in patients with moderate to severe renal impairment.
| |
| | |
| ===Hepatic Impairment===
| |
| | |
| ZETIA is not recommended in patients with moderate to severe [[hepatic impairment]] [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].
| |
| | |
| ZETIA given concomitantly with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations of hepatic transaminase levels [seeContraindications (4); Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ZETIA (EZETIMIBE) TABLET [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a773b0b2-d31c-4ff4-b9e8-1eb2d3a4d62a | publisher = | date = | accessdate = 11 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Hypolipidemic agents]]
| |
| [[Category:Lactams]]
| |
| [[Category:Merck]]
| |
| [[Category:Schering-Plough]]
| |
| [[Category:Azetidines]]
| |
| [[Category:Organofluorides]]
| |
| [[Category:Phenols]]
| |
| [[Category:Cardiovasuclar Drugs]]
| |
| [[Category:Drugs]]
| |